Company Overview

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.

INOVIQ’s headquarters are based in Melbourne, Australia, and we have representation in the USA with a dedicated team of 19 employees, including 11 R&D members who collectively hold 8 PhDs. Our expertise spans research, development, clinical testing, and commercialisation. The Company has facilities for cGMP production and is compliant with ISO17025.

Our Mission
INOVIQ is committed to developing next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives.
Company History

The Company was established in 2016, as has strategically grown through multiple acquisitions and in-licensing to expand our technology portfolio.

Company History Timeline